22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22...

Home / News / Pearce IP Blog
22 MAR 2024 | AU | Samsung Bioepis Seeks to Revoke Janssen’s Stelara® (ustekinumab) Patents in Australian Court On 22...
15 MAR 2024 | AU | November 2023 PBAC Public Summary Documents Feature Biopharma On 15 March 2024, the Australian...
On 5 March 2024, the Australian Patent Office (APO) issued its decision in the opposition filed by Clearview Towing Mirrors Pty Ltd in respect of Australian patent application AU2020281026 (Opposed Application). Clearview had opposed the grant of the Opposed Application on the grounds of inventive step, novelty, sufficiency, support and clarity.
9 MAR 2024 US | Samsung Bioepis Presents Interchangeability Updates for its Adalimumab and Ustekinumab Biosimilars at...
On 16 February 2024, IP Australia published that Ono Pharmaceutical Co. Ltd (Ono) was granted a patent term extension (PTE) in respect of its Australian Patent No. 2011203119 (Patent). This is the quiet conclusion to Ono’s dispute with the Patent Office relating to OPTIVO® (nivolumab) which culminated in an appeal court decision rejecting its previous application for PTE.
1 MAR 2024 | AU | Authorities raid Como Compounding Pharmacy in Melbourne and Seize Semaglutide The Australian...
The Federal Court’s second patent decision of 2024 is a unanimous decision of the Full Federal Court relating to one of several long-running patent disputes in the field of carpark overstay detection. In March 2023, Justice Besanko upheld the validity of two patents owned by Vehicle Monitoring Systems Pty Ltd (VMS), both entitled ‘Method, apparatus and system for parking overstay detection’.
In the first Federal Court patent decision handed down in 2024, MSA 4×4 Accessories Pty Ltd failed to establish infringement by Clearview Towing Mirrors Pty Ltd of MSA’s patent to a mountable storage device, commonly used in off-road and trade vehicles.
23 FEB 2024 | EU | Samsung Bioepis Presented Study Results for ustekinumab SB17, Biosimilar to Janssen’s Stelara®, at...
19 JAN 2024 | AU | March a Bumper Month for Biopharma at the Pharmaceutical Benefits Assessment Committee (PBAC) in...
09 FEB 2024 | AU | Biocon Biologics Enter a Five-year Exclusive Partnership with Sandoz in Australia for Trastuzumab...
On 24 January 2024 New Zealand introduced a new IP Bill for Geographical Indications (GIs). The bill will amend NZ law...
26 JAN 2024 | SG | AbbVie to Expand Biologics Manufacturing Facility in Singapore with US$223M Investment AbbVie...
19 JAN 2024 | US | Alvotech Provides Update on FDA Facility Inspection for AVT02 and AVT04 Alvotech announced that its...
The High Court of New Zealand is only rarely called on to determine applications for interlocutory injunctions in proceedings alleging patent infringement. The decision in this case was that, despite taking more than a
12 JAN 2024 | EU | Celltrion Wins European Bids for Yuflyma® (adalimumab) and Remsima® (infliximab) Korea Biomedical...